iSpecimen Statistics
Total Valuation
iSpecimen has a market cap or net worth of $3.80 million. The enterprise value is -$2.81 million.
Important Dates
The next estimated earnings date is Monday, May 18, 2026, after market close.
| Earnings Date | May 18, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
iSpecimen has 29.66 million shares outstanding. The number of shares has increased by 547.46% in one year.
| Current Share Class | 29.66M |
| Shares Outstanding | 29.66M |
| Shares Change (YoY) | +547.46% |
| Shares Change (QoQ) | +32.06% |
| Owned by Insiders (%) | 0.00% |
| Owned by Institutions (%) | 0.58% |
| Float | 29.66M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.97 |
| Forward PS | n/a |
| PB Ratio | 0.35 |
| P/TBV Ratio | 4.64 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.12, with a Debt / Equity ratio of 0.09.
| Current Ratio | 1.12 |
| Quick Ratio | 1.11 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -905.21 |
Financial Efficiency
Return on equity (ROE) is -327.77% and return on invested capital (ROIC) is -160.77%.
| Return on Equity (ROE) | -327.77% |
| Return on Assets (ROA) | -59.44% |
| Return on Invested Capital (ROIC) | -160.77% |
| Return on Capital Employed (ROCE) | -272.05% |
| Weighted Average Cost of Capital (WACC) | 14.33% |
| Revenue Per Employee | $275,571 |
| Profits Per Employee | -$1.50M |
| Employee Count | 7 |
| Asset Turnover | 0.20 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -90.98% in the last 52 weeks. The beta is 1.98, so iSpecimen's price volatility has been higher than the market average.
| Beta (5Y) | 1.98 |
| 52-Week Price Change | -90.98% |
| 50-Day Moving Average | 0.24 |
| 200-Day Moving Average | 0.69 |
| Relative Strength Index (RSI) | 33.16 |
| Average Volume (20 Days) | 37,323,422 |
Short Selling Information
The latest short interest is 3.07 million, so 10.36% of the outstanding shares have been sold short.
| Short Interest | 3.07M |
| Short Previous Month | 939,560 |
| Short % of Shares Out | 10.36% |
| Short % of Float | 10.36% |
| Short Ratio (days to cover) | 0.18 |
Income Statement
In the last 12 months, iSpecimen had revenue of $1.93 million and -$10.49 million in losses. Loss per share was -$2.28.
| Revenue | 1.93M |
| Gross Profit | 24,110 |
| Operating Income | -8.98M |
| Pretax Income | -10.49M |
| Net Income | -10.49M |
| EBITDA | -8.72M |
| EBIT | -8.98M |
| Loss Per Share | -$2.28 |
Full Income StatementBalance Sheet
The company has $6.88 million in cash and $268,798 in debt, with a net cash position of $6.61 million or $0.22 per share.
| Cash & Cash Equivalents | 6.88M |
| Total Debt | 268,798 |
| Net Cash | 6.61M |
| Net Cash Per Share | $0.22 |
| Equity (Book Value) | 3.09M |
| Book Value Per Share | 0.36 |
| Working Capital | 723,284 |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$4.24 million and capital expenditures -$454, giving a free cash flow of -$4.24 million.
| Operating Cash Flow | -4.24M |
| Capital Expenditures | -454 |
| Depreciation & Amortization | 260,029 |
| Net Borrowing | n/a |
| Free Cash Flow | -4.24M |
| FCF Per Share | -$0.14 |
Full Cash Flow StatementMargins
| Gross Margin | 1.25% |
| Operating Margin | -465.42% |
| Pretax Margin | -543.68% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
iSpecimen does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -547.46% |
| Shareholder Yield | -547.46% |
| Earnings Yield | -276.01% |
| FCF Yield | -111.61% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on September 16, 2024. It was a reverse split with a ratio of 1:20.
| Last Split Date | Sep 16, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
iSpecimen has an Altman Z-Score of -14.56 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -14.56 |
| Piotroski F-Score | 2 |
